drugset / Trial / NCT03183752

Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules

NCT03183752 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

It has been shown that insulin might be involved in the pathogenesis of thyroid growth. Objective To evaluate the impact of IR and metformin use on the volume of benign thyroid nodules (TNs). Methods A randomized clinical trial to placebo (P) or MTF use. Previous fine needle aspiration confirming the diagnosis is necessary to inclusion. Patients will receive similar tablets of MTF and placebo and instruct to take 3 tablets/day of MTF (500mg/tablet). Thyroid volume, as TN volume, will be assess by ultrasound, both in the beginning, six months and one year after randomization, by the same researcher blinded regarding location group. Blood samples to measure: TSH, FT4, TPO-Ab, lipid profile, glucose and insulin were done after 8h fasting.

Timeline

Start
2015-08-13
Primary completion
2018-10-17
Completion
2019-04-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg —